Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody� technology, in combination with Homspera�, an adjuvant developed by ImmuneRegen BioSciences, Inc.� has produced encouraging anti-tumour results in animal models. The vaccine, known as SCIB2, stimulates immune responses to the lung cancer antigen NY-ESO-1 and may also have potential utility in oesophageal, liver, gastric, prostate, ovarian and bladder cancers...
No comments:
Post a Comment